Abstract:This paper focused on development and evaluation of anti-μ chain IgM ELISA and indirect ELISA for IgG antibodies against hepatitis E virus(HEV).Prokaryotic expressed polymerized recombinant HEV protein NE2 was used as antigen to develop two ELISA methods for anti-HEV IgM(E2-IgM)or IgG(E2-IgG)detection.Serial serum samples of twenty-nine HEV experimentally infected Rhesus monkeys were used to understand the dynamics of anti-HEV IgM and IgG detected by E2-IgM or E2-IgG as well as IgG detected by a generally used commercial kit(Genelabs, anti-HEV IgG,GL-IgG).Sera of 928 normal individuals and 510 clinical acute hepatitis patients were detected for anti-HEV IgM using E2-IgM,among them 200 patients were detected by E2-IgG at the same time.Sera of 5060 normal population were detected for anti-HEV IgG using E2-IgG.Sera of 119 non-A to C acute hepatitis cases were detected parallel for anti-HEV IgM using E2-IgM and a commercial IgM kit(GL-IgM).Two anti-HEV monoclonal antibodies which can capture HEV directly were used in blocking test for the evaluation of the specificity of E2-IgM and E2-IgG. The results showed the positive seroconversion rate of HEV by E2-IgM and E2-IgG methods in 29 HEV infected monkeys were both 100%,of which 75% were conversed within first 4 weeks post-infection,all earlier than the beginning time of ALT abnormality. Compared with 79.3% seroconversion rate by GL-IgG, 75% seroconversed within the first six weeks,much later than ALT abnormality. The seroconversion rate by E2-IgM lasted from two to fourteen weeks,with a mean of six weeks.Seroconversion by E2-IgG was a little later than E2-IgM, but none converted to negative at 70 weeks after infection. The average lasting time of GL-IgG was 18 weeks, only one monkey's IgG remained to be detectable by GL-IgG at 70weeks post infection. Among 928 normal people samples detected by E2-IgM,only 2 had OD value a little higher than 0.2.Two groups could be easily differentiated from 510 clinical acute hepatitis patients detected by E2-IgM ,one group was the same as detected in normal people with OD value lower than 0.2, the other group including 131 patients had OD value higher than 0.4,among them 109 samples were higher than 1.0. It suggested these two groups were corresponding to non-hepatitis E and hepatitis E patients.Patients with E2-IgM positive also had higher E2-IgG OD.Among 119 non-A to C acute hepatitis patients detected by E2-IgM and GL-IgM parallelly,57 were E2-IgM positive,including all the 29 patients who were positive by GL-IgM.Ten E2-IgM positive samples could be blocked by anti-HEV monoclonal antibodies(MAbs)from 66.4%～94.8%,with an average blocking rate of 86.6%.The OD values of 5060 normal population detected by E2-IgG formed a peak close to logarithm normal distribution with the mean of 0.022,and distributed evenly in samples with OD value higher than 0.4.Two groups also could be differentiated from 200 acute hepatitis patients,one with OD value lower than 0.2 as same as normal people,and the other with OD value higher than 1.0 formed another peak with peak OD value of 2.5,among the latter peak most were E2-IgM positive.Anti-HEV MAbs also could block E2-IgG effectively,and the blocking rate of Fab fragments of MAbs were the same as whole MAbs,which suggested that the blocking is epitope specific.The developed IgM and IgG ELISA methods have good specificity and sensitivity.IgM method is suitable for diagnosis of hepatitis E virus clinically infected,and the IgG method is suitable to diagnose hepatitis E virus infection in the past.

Application of P166 Recombinant Proteins Derived from Different Genotypes of Hepatitis E Virus (HEV) in Anti- HEV Antibody Detection

Development of a competitive ELISA for detecting antibodies against genotype 1 hepatitis E virus

Establishment of enzyme-linked immunosorbent assay one-step assay based on recombinant proteins derived from different genotypes of hepatitis E virus

A Valuable Antigen Detection Method for Diagnosis of Acute Hepatitis E

Application of truncated immunodominant polypeptide from hepatitis E virus (HEV) ORF2 in an assay to exclude nonspecific binding in detecting anti-HEV immunoglobulin M.

Identification Of Type - Common And Neutralization Epitopes On Hepatitis E Virus Genotype 4 By Using Monoclonal Antibodies

Double-Antigen Enzyme-Linked Immunosorbent Assay for Detection of Hepatitis E Virus-Specific Antibodies in Human or Swine Sera

Detection of specific IgM antibodies against hepatitis E virus by ELISA based on immunodominant ORF2 polypeptide

Identification and characterization of neutralizing antigen epitope of hepatitis E virus clustered in genotype IV

Establishment of competitive binding assay to detect and differentiate hepatitis E virus infection.

Establishment of Real Time PCR Assay for Hepatitis E Virus from Swine and Its Molecular Epidemiology

A New Enzyme Immunoassay for the Detection of Antibody to Hepatitis E Virus.

Evaluation of the Diagnostic Kits for Hepatitis E and Establishment of a Quantification Method for De-Tecting Anti-Hey IgG

Establishment and Primary Application of Double Antigen Sandwich ELISA for Detection of Hepatitis E Virus Antibody

Redeveloping Antigen Detection Kits for the Diagnosis of Rat Hepatitis E Virus.

Detection of Hev Antigen As A Novel Marker for the Diagnosis of Hepatitis E

Development and Evaluation of ELISAs for Anti-hepatitis E Virus IgM and IgG Detection Based on Polymerized Recombinant Antigen

Design and Preliminary Application of a Set of Highly Sensitive Universal RT-PCR Primers for Detecting Genotype Ⅰ/Ⅳ Hepatitis E Virus

Antigenic Composition and Immunoreactivity Differences Between HEV Recombinant Capsid Proteins Generated from Different Genotypes.

Research and Application of the Diagnostic Kit for Anti-Hepatitis E Virus IgG Detection

An Optimized High-Throughput Neutralization Assay For Hepatitis E Virus (Hev) Involving Detection Of Secreted Porf2